1. Academic Validation
  2. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation

  • Clin Cancer Res. 2015 May 15;21(10):2338-47. doi: 10.1158/1078-0432.CCR-14-3000.
Masanori Hasegawa 1 Raj Kumar Sinha 2 Manoj Kumar 2 Maroof Alam 1 Li Yin 1 Deepak Raina 3 Akriti Kharbanda 1 Govind Panchamoorthy 3 Dikshi Gupta 2 Harpal Singh 4 Surender Kharbanda 3 Donald Kufe 5
Affiliations

Affiliations

  • 1 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • 2 Center for Biomedical Engineering, Indian Institute of Technology, New Delhi, India.
  • 3 Genus Oncology, Boston, Massachusetts.
  • 4 Center for Biomedical Engineering, Indian Institute of Technology, New Delhi, India. donald_kufe@dfci.harvard.edu harpal2000@yahoo.com.
  • 5 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. donald_kufe@dfci.harvard.edu harpal2000@yahoo.com.
Abstract

Purpose: The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating Cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities.

Experimental design: Encapsulation of the MUC1-C inhibitor GO-203 in novel polymeric nanoparticles was studied for effects on intracellular targeting of MUC1-C signaling and function.

Results: Our results show that loading GO-203 into tetrablock polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG copolymers is achievable and, notably, is enhanced by increasing PEG chain length. In addition, we found that release of GO-203 from these nanoparticles is controllable over at least 7 days. GO-203/nanoparticle treatment of MUC1-C-positive breast and lung Cancer cells in vitro was more active with less frequent dosing than that achieved with nonencapsulated GO-203. Moreover, treatment with GO-203/nanoparticles blocked MUC1-C homodimerization, consistent with on-target effects. GO-203/nanoparticle treatment was also effective in downregulating TIGAR, disrupting redox balance, and inhibiting the self-renewal capacity of Cancer cells. Significantly, weekly administration of GO-203/nanoparticles to mice bearing syngeneic or xenograft tumors was associated with regressions that were comparable with those found when dosing on a daily basis with GO-203.

Conclusions: These findings thus define an effective approach for (i) sustained administration of GO-203 in polymeric PLA-(PEG-PPG-PEG) nanoparticles to target MUC1-C in Cancer cells and (ii) the potential delivery of other Anticancer peptide drugs.

Figures
Products